Moderna, Inc. $MRNA Stock Position Raised by Cetera Investment Advisers

Cetera Investment Advisers grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 26.2% in the 2nd quarter, Holdings Channel reports. The firm owned 62,131 shares of the company’s stock after acquiring an additional 12,916 shares during the quarter. Cetera Investment Advisers’ holdings in Moderna were worth $1,714,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Jump Financial LLC boosted its stake in Moderna by 5,590.0% during the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock valued at $25,584,000 after purchasing an additional 886,567 shares in the last quarter. FORA Capital LLC grew its holdings in Moderna by 31.7% during the first quarter. FORA Capital LLC now owns 97,072 shares of the company’s stock worth $2,752,000 after acquiring an additional 23,344 shares during the period. Charles Schwab Investment Management Inc. raised its position in Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after acquiring an additional 285,662 shares in the last quarter. SHANDA ASSET MANAGEMENT HOLDINGS Ltd acquired a new stake in Moderna in the 1st quarter valued at about $28,350,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Moderna by 28.8% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 659,250 shares of the company’s stock valued at $18,690,000 after acquiring an additional 147,267 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Wolfe Research reaffirmed an “underperform” rating and issued a $17.00 price objective on shares of Moderna in a research note on Thursday, November 20th. Berenberg Bank set a $28.00 price target on Moderna in a report on Monday, November 17th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Royal Bank Of Canada cut their target price on Moderna from $28.00 to $25.00 and set a “sector perform” rating on the stock in a research report on Friday, November 21st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $63.00 price target (down previously from $69.00) on shares of Moderna in a research report on Friday, November 21st. Two research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, Moderna currently has a consensus rating of “Reduce” and a consensus target price of $29.46.

Moderna Stock Up 3.3%

Shares of Moderna stock opened at $25.84 on Monday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $48.92. The stock has a market cap of $10.10 billion, a PE ratio of -3.20 and a beta of 2.02. The business has a fifty day simple moving average of $25.88 and a 200-day simple moving average of $26.99.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same period in the prior year, the business earned $0.03 EPS. The business’s revenue for the quarter was down 45.4% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.